Medovex’ Denervex used in first human cases

118
Medovex Denervex

The first human cases using Medovex’ Denervex rotacapsulation for the treatment of facet joint syndrome have taken place in Manchester, UK.

The DenerveX system—which recently received CE mark—is a new device designed for enduring relief of facet joint syndrome related to lower back pain.

Jarrett Gorlin, Medovex’ chief executive officer, states, “Our first human use cases for the DenerveX system… took place… with very encouraging initial procedural success. We anticipate performing up to as many as 30 plus additional procedures by the end of August.”

Patrick Kullmann, Medovex president and chief operating officer adds, “The DenerveX treatment uses ‘rotacapsulation,’ a combination of high heat and rotational capsular tissue shaving, in a minimally invasive posterior procedure for the treatment of facet joint syndrome.”

The system is designed to denervate and removes capsular tissue from the facet joint in one procedure. Treatment results from the combined effect of a deburring or polishing action and radiofrequency ablation treatment on the facet joint. Using this new technique, the slowly rotating burr removes the targeted facet joint synovial membrane and joint surface while the heat ablation destroys tissue and denudes any residual nervous and synovial membrane overlying the joint, removing the end point sensory tissue of the joint.

The DenerveX system consists of the DenerveX Kit which contains the DenerveX device, a single use medical device and the DenerveX Pro-40 power generator. DenerveX system is not US Food and Drug Administration cleared.

LEAVE A REPLY